Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1165734 | 0.77 | NOTUM (0.60) | NOTUMNPC1RAB9AALDH1A1HPGD | |
| SCHEMBL6769133 | 0.75 | SIGMAR1 (0.72) | SIGMAR1TMPRSS2HTR1AADRA2ACYP2D6 | |
| Hydrochloric Acid SCHEMBL8068550 | 0.74 | SIGMAR1 (0.70) | SIGMAR1TMPRSS2HTR1AADRA2ACYP2D6 | |
| SCHEMBL4190832 | 0.73 | CA12 (0.52) | TSHRNOTUMNPC1RAB9AALDH1A1 | |
| SCHEMBL698549 | 0.73 | TSHR (0.63) | TSHRCNR2LMNARAB9AALDH1A1 | |
| SCHEMBL6714690 | 0.72 | GAA (0.53) | SIGMAR1TSHRNOTUMLMNANPC1 | |
| SCHEMBL697671 | 0.72 | HPGD (0.68) | LMNANPC1RAB9AALDH1A1HPGD | |
| SCHEMBL20914962 | 0.70 | GPR119 (0.43) | NOTUMNPC1RAB9AL3MBTL1 | |
| SCHEMBL1419127 | 0.69 | MAPT (0.34) | CYP2D6MAOATSHRNOTUMPMP22 | |
| SCHEMBL6228834 | 0.68 | NOTUM (0.62) | TSHRNOTUMLMNAL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2004-05-27 | — | — | US | claimed |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | G.D. SEARLE & CO. | 2003-11-27 | — | — | US | claimed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | claimed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | claimed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | claimed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | claimed |
| US-20230310358-A1 | Compositions And Methods For Treating Autism | YAMO PHARMACEUTICALS LLC (US) | 2023-10-05 | — | — | US | disclosed |
| US-20220211650-A1 | SUSTAINED RELEASE FORMULATIONS | HOFFMAN TECHNOLOGIES LLC | 2022-07-07 | — | — | US | disclosed |
| EP-3955910-A1 | SUSTAINED RELEASE FORMULATIONS | Hoffman Technologies LLC. (US) | 2022-02-23 | — | — | EP | disclosed |
| US-20210338619-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | YAMO PHARMACEUTICALS LLC | 2021-11-04 | — | — | US | disclosed |
| EP-3823626-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | Yamo Pharmaceuticals LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| EP-3823593-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | Yamo Pharmaceuticals LLC (US) | 2021-05-26 | — | — | EP | disclosed |
| US-20210128508-A1 | Compositions And Methods For Treating Autism | YAMO PHARMACEUTICALS LLC (US) | 2021-05-06 | — | — | US | disclosed |
| EP-0484437-A4 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | SEARLE & CO (US) | 1994-06-01 | — | — | EP | disclosed |
| EP-0484437-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. Searle & Co. (US) | 1992-05-13 | — | — | EP | disclosed |
| WO-1992001667-A1 | RENAL-SELECTIVE PRODRUGS FOR CONTROL OF RENAL SYMPATHETIC NERVE ACTIVITY IN THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1992-02-06 | — | — | WO | disclosed |
| WO-1991001724-A1 | RENAL-SELECTIVE PRODRUGS FOR THE TREATMENT OF HYPERTENSION | G.D. SEARLE & CO. (US) | 1991-02-21 | — | — | WO | disclosed |
| US-4170654-A | Antihypertensive compositions containing N-heterocyclicalanines and α- | MERCK & CO., INC. (US) | 1979-10-09 | — | — | US | disclosed |
| US-4160835-A | Antihypertensive compositions containing an arylsubstituted alanine and a phenyl hydrazinopropionic acid | MERCK & CO., INC. (US) | 1979-07-10 | — | — | US | disclosed |
| US-4156734-A | Antihypertensive compositions containing an aryl-substituted alanine azo and an arylhydrazino-propionic acid | MERCK & CO., INC. (US) | 1979-05-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310358-A1 | Compositions And Methods For Treating Autism | MECP2, AADAT, CHAT | SIGMAR1 2834/4885TMPRSS2 3409/4885HTR1A 75/4885 |
| US-20220211650-A1 | SUSTAINED RELEASE FORMULATIONS | TH, PAH, COMT | SIGMAR1 245/4885TMPRSS2 1596/4885HTR1A 122/4885 |
| US-20210338619-A1 | COMPOSITIONS AND METHODS FOR TREATING AUTISM | MECP2, AADAT, CHAT | SIGMAR1 2831/4885TMPRSS2 3492/4885HTR1A 69/4885 |
| US-20030220521-A1 | Renal-selective prodrugs for control of renal sympathetic nerve activity in the treatment of hypertension | GLS, APEH, GGH | SIGMAR1 2218/4885TMPRSS2 1373/4885HTR1A 1948/4885 |
| US-20210128508-A1 | Compositions And Methods For Treating Autism | MECP2, AADAT, CHAT | SIGMAR1 2834/4885TMPRSS2 3409/4885HTR1A 75/4885 |
| US-20040101523-A1 | Renal-selective prodrugs for control of renal smpathetic nerve activity in the treatment of hypertension | GLS, DBH, APEH | SIGMAR1 1779/4885TMPRSS2 952/4885HTR1A 1663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.